# A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

> **NCT04454567** · PHASE2 · TERMINATED · sponsor: **Assembly Biosciences** · enrollment: 2 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** ABI-H0731
- **DRUG:** Placebo
- **DRUG:** NrtI

## Key facts

- **NCT ID:** NCT04454567
- **Lead sponsor:** Assembly Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-11
- **Primary completion:** 2021-04-08
- **Final completion:** 2021-04-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study stopped due to a change in the Sponsor's overall development strategy from treatment of chronic disease to finite, curative treatments, and is based partially on the advice and feedback from experts and regulators.
- **Last updated:** 2022-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04454567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04454567, "A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04454567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*